Stocks and Investing
Stocks and Investing
Tue, May 16, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Luca Issi Reiterated (VERV) at Buy and Held Target at $35 on, May 16th, 2023
Luca Issi of RBC Capital, Reiterated "Verve Therapeutics, Inc." (VERV) at Buy and Held Target at $35 on, May 16th, 2023.
Luca has made no other calls on VERV in the last 4 months.
There are 2 other peers that have a rating on VERV. Out of the 2 peers that are also analyzing VERV, 1 agrees with Luca's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Rick Bienkowski of "Cantor Fitzgerald" Initiated at Hold and Held Target at $21 on, Wednesday, February 1st, 2023
This is the rating of the analyst that currently disagrees with Luca
- Whitney Ijem of "Canaccord Genuity" Initiated at Strong Buy and Held Target at $29 on, Thursday, April 13th, 2023
Contributing Sources